BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8532404)

  • 1. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
    Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
    Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
    Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
    Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
    Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
    In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
    Brivio F; Lissoni P; Barni S; Tancini G; Ardizzoia A; Erba L; Alderi G; Nociti V
    Eur J Surg; 1993 Jan; 159(1):43-7. PubMed ID: 8095806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue.
    Nielsen HJ; Hansen U; Christensen IJ; Reimert CM; Brünner N; Moesgaard F
    J Pathol; 1999 Dec; 189(4):487-95. PubMed ID: 10629548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H; Yamaguchi Y
    Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
    Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
    Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic strategies in colorectal cancer].
    Flieger D; Keller R; Fischbach W
    Dtsch Med Wochenschr; 2003 Sep; 128(37):1902-7. PubMed ID: 12970825
    [No Abstract]   [Full Text] [Related]  

  • 11. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
    Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
    Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
    Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
    Kapoor S; Pal S; Sahni P; Dattagupta S; Kanti Chattopadhyay T
    J Surg Res; 2005 Dec; 129(2):172-5. PubMed ID: 15882879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
    Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma.
    Fernández-Aceñero MJ; Galindo-Gallego M; Sanz J; Aljama A
    Cancer; 2000 Apr; 88(7):1544-8. PubMed ID: 10738211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.